SF
TGTX icon

Summit Financial’s TG Therapeutics TGTX Stock Holding History

Summit Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Buy
95,303
+9,910
+12% +$406K 0.06% 335
2026
Q1 		$2.84M Sell
85,393
-4,733
-5% -$141K 0.04% 475
2025
Q4 		$2.69M Buy
+90,126
New +$2.94M 0.04% 412

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Summit Financial's TGTX Position: Q2 2026 in Review

Summit Financial increased its TG Therapeutics (TGTX) stake by 12% in Q2 2026, buying an estimated $406K and bringing the position to 95,303 shares worth $5.24M. The position accounts for 0.06% of the portfolio, ranked #335.

Summit Financial first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Summit Financial held 95,303 shares of TG Therapeutics worth $5.24M as of Q2 2026.
  • Summit Financial bought 9,910 TG Therapeutics shares in Q2 2026, an estimated $406K.
  • TG Therapeutics made up 0.06% of Summit Financial's portfolio in Q2 2026, its #335 holding.
  • Summit Financial first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.